Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $175.00

Posted by Geri Gentry on Aug 9th, 2026

Protagonist Therapeutics (NASDAQ:PTGX – Free Report) had its price objective raised by Citigroup from $130.00 to $175.00 in a research note published on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other brokerages have also recently commented on PTGX. Barclays boosted their price target on shares of Protagonist Therapeutics from $151.00 to $153.00 and gave the stock an “overweight” rating in a research note on Thursday. Wolfe Research initiated coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 price objective for the company. Truist Financial lifted their target price on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Friday, May 15th. Finally, Wedbush boosted their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.71.

Get Our Latest Report on PTGX

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $145.87 on Thursday. Protagonist Therapeutics has a 1 year low of $50.49 and a 1 year high of $148.00. The firm’s 50 day moving average price is $124.30 and its 200-day moving average price is $105.22. The stock has a market cap of $9.38 billion, a P/E ratio of 141.62 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. The firm had revenue of $213.47 million during the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The company’s quarterly revenue was up 3746.8% on a year-over-year basis. As a group, equities analysts expect that Protagonist Therapeutics will post 3.51 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This trade represents a 12.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 102,000 shares of company stock worth $10,436,340 in the last 90 days. 5.19% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its stake in Protagonist Therapeutics by 30.6% during the first quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after acquiring an additional 2,334 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Protagonist Therapeutics by 283.6% in the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock valued at $6,493,000 after purchasing an additional 99,269 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $987,000. Finally, Guggenheim Capital LLC boosted its holdings in shares of Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after purchasing an additional 303 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics News Summary

Here are the key news stories impacting Protagonist Therapeutics this week:

Positive Sentiment: Protagonist reported quarterly earnings of $2.29 per share, exceeding the $2.27 consensus estimate, while revenue of $213.5 million also topped expectations. The results helped PTGX reach a new one-year high. Protagonist Therapeutics Reaches New 1-Year High on Earnings Beat
Positive Sentiment: Citigroup raised its price target for PTGX to $175, implying additional upside from recent trading levels and signaling continued confidence in the company’s outlook. Citigroup Raises Protagonist Therapeutics Price Target
Positive Sentiment: Zacks said rising earnings estimates could support further near-term gains, adding to the bullish momentum following the company’s strong results. Surging Earnings Estimates Signal Upside for Protagonist Therapeutics
Neutral Sentiment: Wall Street Zen listed PTGX at a Buy rating, although the article’s “downgraded” wording makes the precise rating change unclear. Protagonist Therapeutics Rating Report
Negative Sentiment: HC Wainwright cut its 2026 EPS forecast to $4.00 from $4.72 and reduced its Q3 estimate to $2.55 from $2.88. It also projects losses in Q4 2026, 2027 and 2028, which highlights potential earnings volatility despite the current-year consensus estimate of $3.69 per share.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.